Skip to main navigation Skip to search Skip to main content

Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer

  • Shailesh Mahesh Advani
  • , Pragati Shailesh Advani
  • , Derek W. Brown
  • , Stacia M. Desantis
  • , Krittiya Korphaisarn
  • , Helena M. Vonville
  • , Jan Bressler
  • , David S. Lopez
  • , Jennifer S. Davis
  • , Carrie R. Daniel
  • , Amir Mehrvarz Sarshekeh
  • , Dejana Braithwaite
  • , Michael D. Swartz
  • , Scott Kopetz
  • The University of Texas MD Anderson Cancer Center
  • Georgetown University Medical Center
  • National Human Genome Research Institute (NHGRI)
  • National Cancer Institute (NCI)
  • University of Texas Health Sciences Center (UTHealth)
  • Univ. of Texas Med. Sch. at Houston
  • University of Texas Medical Branch

Research output: Contribution to journal › Article › peer-review

33 Citations (Scopus)

Abstract

Background: CpG Island Methylator Phenotype (CIMP) is an epigenetic phenotype in CRC characterized by hypermethylation of CpG islands in promoter regions of tumor suppressor genes, leading to their transcriptional silencing and loss of function. While the prevalence of CRC differs across geographical regions, no studies have compared prevalence of CIMP-High phenotype across regions. The purpose of this project was to compare the prevalence of CIMP across geographical regions after adjusting for variations in methodologies to measure CIMP in a meta-analysis. Methods: We searched PubMed, Medline, and Embase for articles focusing on CIMP published from 2000 to 2018. Two reviewers independently identified 111 articles to be included in final meta-analysis. We classified methods used to quantify CIMP into 4 categories: a) Classical (MINT marker) Panel group b) Weisenberg-Ogino (W-O) group c) Human Methylation Arrays group and d) Miscellaneous group. We compared the prevalence of CIMP across geographical regions after correcting for methodological variations using meta-regression techniques. Results: The pooled prevalence of CIMP-High across all studies was 22% (95% confidence interval:21-24%; I2 = 94.75%). Pooled prevalence of CIMP-H across Asia, Australia, Europe, North America and South America was 22, 21, 21, 27 and 25%, respectively. Meta-regression analysis identified no significant differences in the prevalence of CIMP-H across geographical regions after correction for methodological variations. In exploratory analysis, we observed variations in CIMP-H prevalence across countries. Conclusion: Although no differences were found for CIMP-H prevalence across countries, further studies are needed to compare the influence of demographic, lifestyle and environmental factors in relation to the prevalence of CIMP across geographical regions.

Original languageEnglish
Article number964
JournalBMC Cancer
Volume19
Issue number1
DOIs
Publication statusPublished - 17 Oct 2019
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • CIMP
  • Colorectal
  • Epigenetics
  • Geographic
  • Methylation

Fingerprint

Dive into the research topics of 'Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer'. Together they form a unique fingerprint.

Cite this